Opko Health Inc. (NASDAQ:OPK) VP Steven D. Rubin acquired 6,000 shares of Opko Health stock in a transaction that occurred on Wednesday, March 7th. The shares were purchased at an average cost of $3.25 per share, with a total value of $19,500.00. Following the purchase, the vice president now owns 5,691,915 shares of the company’s stock, valued at approximately $18,498,723.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
OPK stock traded down $0.13 during midday trading on Monday, reaching $3.04. The company had a trading volume of 3,928,077 shares, compared to its average volume of 4,980,257. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.14 and a quick ratio of 0.98. Opko Health Inc. has a 1 year low of $2.66 and a 1 year high of $8.03. The stock has a market cap of $1,773.53, a PE ratio of -10.48 and a beta of 1.56.
Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Opko Health had a negative return on equity of 7.87% and a negative net margin of 28.93%. The company had revenue of $193.70 million during the quarter, compared to analysts’ expectations of $307.44 million. research analysts expect that Opko Health Inc. will post -0.48 EPS for the current fiscal year.
Several brokerages recently commented on OPK. Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. JPMorgan Chase cut shares of Opko Health from a “neutral” rating to an “underweight” rating and set a $7.00 price target for the company. in a research note on Friday, March 2nd. ValuEngine cut shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. BidaskClub cut shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 10th. Finally, Cantor Fitzgerald set a $20.00 price target on shares of Opko Health and gave the stock a “buy” rating in a research note on Thursday, March 1st. Four analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Opko Health currently has a consensus rating of “Hold” and an average price target of $11.29.
COPYRIGHT VIOLATION WARNING: This piece was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/04/02/insider-buying-opko-health-inc-opk-vp-purchases-19500-00-in-stock/2009601.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.